» Authors » Namita D Shanbhag

Namita D Shanbhag

Explore the profile of Namita D Shanbhag including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 60
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Y, Fan Y, Xu J, Huo L, Scott A, Jin J, et al.
J Exp Clin Cancer Res . 2022 Aug; 41(1):257. PMID: 35996148
Background: G protein-coupled receptor (GPCR) is the most targeted protein family by the FDA-approved drugs. GPCR-kinase 3 (GRK3) is critical for GPCR signaling. Our genomic analysis showed that GRK3 expression...
2.
Song S, Xu Y, Huo L, Zhao S, Wang R, Li Y, et al.
J Exp Clin Cancer Res . 2021 Jun; 40(1):207. PMID: 34162421
Background: Gastric adenocarcinoma with peritoneal carcinomatosis (PC) is therapy resistant and leads to poor survival. To study PC in depth, there is an urgent need to develop representative PC-derived cell...
3.
Katz R, Zaidi T, Pujara D, Shanbhag N, Truong D, Patil S, et al.
Cancer Cytopathol . 2020 Apr; 128(8):553-562. PMID: 32320527
Background: Approximately one third of needle biopsies that are performed to rule out malignancy of indeterminate pulmonary nodules detected radiologically during lung cancer screening are negative, thus exposing cancer-free patients...
4.
Song S, Li Y, Xu Y, Ma L, Pizzi M, Jin J, et al.
Mol Oncol . 2020 Mar; 14(6):1410-1426. PMID: 32175692
Hippo/YAP1 signaling is a major regulator of organ size, cancer stemness, and aggressive phenotype. Thus, targeting YAP1 may provide a novel therapeutic strategy for tumors with high YAP1 expression in...
5.
Harada K, Pizzi M, Baba H, Shanbhag N, Song S, Ajani J
Cancer . 2018 Oct; 124(20):3962-3964. PMID: 30368777
No abstract available.